<DOC>
	<DOCNO>NCT01534143</DOCNO>
	<brief_summary>This pilot phase II trial study well give high dose busulfan together bortezomib work treat patient high risk multiple myeloma undergo stem cell transplant . Drugs use chemotherapy , busulfan , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzyme need cell growth . Giving busulfan together bortezomib stem cell transplant may kill cancer cell</brief_summary>
	<brief_title>High Dose Busulfan Bortezomib Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine time engraftment absolute neutrophil count ( &gt; 0.5 x 10^9/L 3 consecutive day ) , platelet ( &gt; 20X 109^/L 3 consecutive day ) . 2 . Incidence severity acute graft-versus-host disease ( GVHD ) use fludarabine ( fludarabine phosphate ) / busulfan / bortezomib preparative regimen triple immune suppression tacrolimus , sirolimus Thymoglobulin ( anti-thymocyte globulin ) . 3 . To determine safety relate combination first six month post transplant , specifically , treatment related mortality grade III IV non hematologic toxicity , base Common Terminology Criteria Adverse Events ( CTCAE ) version 4 ( v4 ) . SECONDARY OBJECTIVES : I . Incidence myeloma progression high risk group patient . II . Incidence transplant relate mortality morbidity . III . Incidence thrombotic thrombocytopenic purpura ( TTP ) sinusoidal obstructive syndrome ( SOS ) . IV . Incidence severity chronic GVHD . V. Incidence opportunistic infection include cytomegalovirus ( CMV ) , herpes simplex virus ( HSV ) , Epstein-Barr virus ( EBV ) reactivation . I . Overall progression free survival ( PFS ) Day 100 , 6 month , 1 &amp; 2 year post transplant . VII . To determine recovery T-cell , B cell , natural killer ( NK ) cell phenotypes post transplant . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -7 -3 , busulfan IV day -6 -3 , bortezomib IV day -2 . GVHD PROPHYLAXIS : Patients receive anti-thymocyte globulin IV day -3 -1 , sirolimus orally ( PO ) day -3 , tacrolimus IV day -3 . Patients undergo allogeneic hematopoietic stem cell transplantation ( HSCT ) day 0 . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ability provide inform consent Karnofsky Performance Status ( KPS ) &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Availability suitable allogeneic hematopoietic stem cell donor ; minimum human leukocyte antigen ( HLA ) 7/8 match relate unrelated donor High risk multiple myeloma poor prognostic feature base one follow criterion : Progressive disease autologous transplant . No le 3 month post auto transplant Progressive stable disease induction chemotherapy use potent myeloma agent Lenalidomide and/or Bortezomib Patients high risk cytogenetic abnormality document conventional cytogenetics fluorescence situ hybridization ( FISH ) ( hypodiploidy , ( 4:14 ) , ( 14:16 ) chromosome translocation , p53 complex cytogenetics ) additionally , chromosome 13 deletion standard cytogenetics Negative betahuman chorionic gonadotropin ( βHCG ) pregnancy test woman , well implementation birth control men woman Patients prior allogeneic transplant , one prior autologous transplant medical reason Prior treatment busulfan gemtuzumab ( Mylotarg ® ) reason Patient history allergy boron , mannitol , bortezomib Creatinine clearance ( CrCl ) = &lt; 50 ml/min Ejection Fraction &lt; 50 % Diffusion capacity carbon monoxide ( DLCO ) &lt; 50 % predict Forced expiratory volume 1 second ( FEV1 ) &lt; 50 % predict Forced vital capacity ( FVC ) &lt; 50 % predict Patients uncontrolled arrhythmia uncontrolled heart disease screening time ; patient coronary heart disease ( recent myocardial infarction , angina , cardiac stent , bypass surgery last 6 month ) need clear stress echo nuclear myocardial perfusion stress test , cardiology consult ; cardiac history discretion principal investigator Liver enzymes &gt; 3 time upper limit normal Bilirubin &gt; 2 mg/dl ( except Gilbert 's disease ) International normalize ratio ( INR ) &gt; 2 Any previous history liver failure , hepatitis , cirrhosis Systemic Amyloidosis Known history hepatitis B , C , human immunodeficiency virus ( HIV ) current uncontrolled infection Grade &gt; I neuropathy Women pregnant lactate Current history alcohol drug abuse Use investigational agent within 30 day enrollment study Any patient ascites Any patient home oxygen Any clinical finding history physical exam would opinion treat physician principal investigator preclude patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>